Lyell Immunopharma raises up to $100M in private placement; initial $50M at $13.32/share

Lyell Immunopharma, Inc.

Initial closing of ~$50M from 3,753,752 shares at $13.32/share on July 25, 2025.
Milestone closing option for another ~$50M upon LYL314 PiNACLE trial milestone within 12 months.
Investor call option to purchase additional shares at $30.73/share before milestone closing.
Proceeds to fund two pivotal-stage trials of LYL314 and extend cash runway into mid-2027.
Resale registration rights granted; securities issued in exempt private placement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.